XenoGesis is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. The core XenoGesis team has an enviable track record of delivery in drug discovery.
It is clear that identifying poor compounds early through scientific rigor is key in preventing progression into more expensive pre-clinical tests. Even a minor improvement in early-stage drug failure prediction will result in significant time and cost savings for R&D companies. Specifically, XenoGesis can identify the potential ‘winners’ and ‘losers’ in a selection of compounds synthesised in drug discovery campaigns. Moreover, providing iterative feedback to the research team based on the results and recommending next steps is a key focus for XenoGesis.
We combine our state-of-the-art in vitro, in vivo and bioanalytical capabilities with our expert pharmacokinetic/pharmacodynamic (PK/PD) data interpretation services.
Using this integrated approach we provide you with the information required to successfully achieve your drug discovery goals.
XenoGesis was acquired by Sygnature Discovery in September 2020.
AcZon is an Italian Company specializing in biotechnology that develops, produces and commercializes Silica Nanoparticles (Nanoprobes) - for diagnostic, clinical and research fields- as well as a range of conventional reagents optimized for various applications as, for example, fluorescent antibodies. People’s Health is the main focus and ultimate goal of our business; our “mission” is basically “To promote and providing Reagents for Diagnostics and Research, with very high brilliance and clarity of image, stability and sensitivity, by offering products and services that speed-up the diagnostic response time, provide a better service to the patient”. AcZon focuses with growing interest on the amazing potentials offered by combining chemistry, biotechnology and nanotechnology. Indeed, on this basis, AcZon has developed and optimized a line of new products (reagents for in vitro diagnostics and research) characterized by outstanding performances. Thanks to its team of researchers (chemists and biologists), all with considerable experience in the synthesis and functionalization of polymers and in the fields of immunology, proteins and bio-conjugations, AcZon has developed, and is now producing, a line of NanoProbes (proprietary technology), based on Silica NanoParticles (NPs), which are not exclusively suitable for diagnostic and clinical applications, but also for chemistry, pharmacy, agriculture and the environment
Silantes GmbH is a spin-off of the Max-Planck-Institute of Biochemistry. We are an SME specialized in the production and marketing of compounds labelled with stable isotopes (SI: 2H, 13C and 15N and combinations thereof) for life sciences.
Our customers are research institutions in academia and pharmacological companies working in the field of NMR structural biology and quantitative mass spectrometry (proteomics and metabolomics).
Silantes` products and services are marketed worldwide, both directly and through distributors.
Silantes technology is based on biochemical and biophysical methods using a variety of different organisms as cell factory for production of fine chemicals.
The product portfolio comprises SI-amino acids, SI-growth media for bacteria and yeast, SI-nucleotides and phosphoramidites, kits for cell culture labelling (SILAC), kits for in vivo labelling of model organisms such as mouse, C.elegans and zebra fish.
Our services include enzymatic and chemical synthesis of SI-labelled oligonucleotides and growth of SI-labelled bacteria and algae according to customers` specification.
AGINKO Research is the premiere CRO for preclinical work in osteoarticular pathologies. We offer a wide range of contract research services to support Drug and Medical Device established companies as well as start-ups and academia. From industry standard protocols to customized research design, our animal models and assays, both on an in vivo or in vitro basis, provide key tools for compound discovery and product development.
Given our expertise, know-how, and network in the field of osteoarticular pathologies, AGINKO today also offers a full range of histology services for your preclinical and clinical trials as well as general consulting services (e.g., regulatory, strategy, financing) devoted to osteoarticular pathologies.
BioCentrum's mission is to create a platform for our clients and partners in order to help them translate innovative discoveries into preclinical candidates with improved chances to become marketed in the least amount of time possible. Our offer is a range of in vitro and in vivo assays that are created toward incorporating preclinical information into your pipeline.